A Phase 3 interventional study of Iron isomaltoside/ferric derisomaltose in Iron Deficiency Anemia and Iron Deficiency Anaemia, sponsored by Pharmacosmos A/S. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-10.
Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 9 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.
Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 20th largest by enrollment, is one of 5 that started in 2017, is one of 18 in phase 3, and was the 11th registered.
601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.
Browse Anemia, Iron-Deficiency studies →9 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:
Sichuan Huiyu Pharmaceutical Co., Ltd · Sites in China
Ages 18+
Hull University Teaching Hospitals NHS Trust · Sites in United Kingdom
Ages 18+
AHS Cancer Control Alberta · Sites in Canada
Ages 18+ · Women only
Children's Hospital Los Angeles · Sites in United States
Ages 16–60 · Women only · Healthy volunteers
Sun Yat-sen University · Sites in China
Ages 18–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 19 · Phase 4 7
First in 2007; this study’s year is marked. 5 started in 2017.
This study's enrollment of 103 is close to the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 121 across the 32 interventional studies. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 32 have an industry lead sponsor. The 10 most frequent:
Pharmacosmos A/S is the lead sponsor of 36 studies on the registry; 5 are open to participants now.
15 studies in Anemia, Iron-Deficiency by Pharmacosmos A/S: none open now, none under way, none of them phase 3. Of 14 finished, 7 (50%) have results posted.
Among the 15 studies in Anemia, Iron-Deficiency by Pharmacosmos A/S, this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2017, is one of 11 in phase 3, and was the 11th registered.
Pharmacosmos A/S’s Anemia, Iron-Deficiency studies by the year they started, since 2007.
3 of the studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05462704Phase 3Women and Infants Hospital of Rhode IslandIntravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy | 2027-03-30 |
| NCT06884280Phase 3Hull University Teaching Hospitals NHS TrustComparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study | 2027-10 |
| NCT04913649dr. P. NoordzijIntravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients | 2026-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, from their registry updates:
Among Pharmacosmos A/S’s 15 in Anemia, Iron-Deficiency:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate safety and efficacy of intravenous (IV) iron isomaltoside/ferric derisomaltose re-dosing, in subjects who were previously treated with iron isomaltoside/ferric derisomaltose.
Among the various formulations of parenteral iron that are currently available, iron isomaltoside/ferric derisomaltose may allow flexibility in terms of high and rapid dosing. Up to now, most clinical trials with intravenous (IV) iron treatment were of 4-12 weeks in duration; longer trials are warranted to follow-up on long-term safety.
The aim of the trial was to evaluate the safety and efficacy of IV iron isomaltoside/ferric derisomaltose re-dosing in subjects who were previously treated with iron isomaltoside/ferric derisomaltose in lead-in trials.
This was a 6-months extension trial lasting 26 weeks. Eligible subjects attended 5 visits: screening, baseline (subjects treated with a single IV dose of 1000 mg iron isomaltoside/ferric derisomaltose), and follow-up visits at week 2, 13, and 26 weeks after the IV dose, for safety and efficacy assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered IV
Drug: Iron isomaltoside/ferric derisomaltose
Drug page: Iron isomaltoside 1000
Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial. The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride from the site's supply and administered over approximately 20 minutes using IV infusion.
Also known as: Monofer®, Monoferric®, Monover®, Monofar®, Monoferro®
Number of Subjects With Adverse Drug Reactions (ADR)
Safety Evaluate the number of subjects with adverse drug reactions (ADRs), defined as AEs that were assessed by the investigator as related or possible related to the investigational product.
Time frame: Baseline to week 26
Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions
Safety. For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity terms that were included in the analysis were those that started or after the first dose of treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: Loss of consciousness; Seizure; Syncope; Unresponsiveness. The potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). Results show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions.
Time frame: Baseline to week 26
Composite Cardiovascular Adverse Events (AEs)
Safety Results show the composite cardiovascular AEs, that started on or after the first dose of treatment (i.e. treatment emergent) up to month 6. The reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). The potential cardiovascular AEs included the following: * Death due to any cause * Non-fatal myocardial infarction * Non-fatal stroke * Unstable angina requiring hospitalisation * Congestive heart failure requiring hospitalisation or medical intervention * Arrhythmias * Hypertension * Hypotension Results show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs.
Time frame: Baseline to week 26
Time to First Composite Cardiovascular Safety AE
Safety Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the Clinical Endpoint Adjudication Committee (CEAC), were considered for this endpoint. Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit.
Time frame: Baseline, week 2, 13, and 26
S-phosphate <2 mg/dL at Any Time From Baseline to Week 26
Safety Results show the number of trial participants and their status of s-phosphate \<2 mg/dL, at any time from baseline to week 26.
Time frame: Baseline to week 26
Change in Hb From Baseline to Week 2, 13, and 26
Efficacy. Change in Hb from baseline to week 2, 13, and 26.
Time frame: Baseline, week 2, 13, and 26
Change in S-ferritin From Baseline to Week 2, 13, and 26
Efficacy. Change in s-ferritin from baseline to week 2, 13, and 26.
Time frame: Baseline, week 2, 13, and 26
Change in Transferrin Saturation (TSAT) From Baseline to Week 2, 13, and 26
Efficacy Change in transferrin saturation (TSAT) from baseline to week 2, 13, and 26. TSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron.
Time frame: Baseline, week 2, 13, and 26
Change in S-iron From Baseline to Week 2, 13, and 26
Efficacy. Change in s-iron from baseline to week 2, 13, and 26.
Time frame: Baseline, week 2, 13, and 26
A total of 193 subjects were screened and 103 subjects were enrolled into the trial.
| Milestone | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Started | 103 |
| Completed | 94 |
| Not completed | 9 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Physician decision | 1 |
| Withdrew: Subject had problems with transportation | 2 |
Safety Evaluate the number of subjects with adverse drug reactions (ADRs), defined as AEs that were assessed by the investigator as related or possible related to the investigational product.
| Participants | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Number of Subjects With Adverse Drug Reactions (ADR) | 5 |
Safety. For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity terms that were included in the analysis were those that started or after the first dose of treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: Loss of consciousness; Seizure; Syncope; Unresponsiveness. The potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). Results show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions.
| Participants | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions | 0 |
Safety Results show the composite cardiovascular AEs, that started on or after the first dose of treatment (i.e. treatment emergent) up to month 6. The reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). The potential cardiovascular AEs included the following: * Death due to any cause * Non-fatal myocardial infarction * Non-fatal stroke * Unstable angina requiring hospitalisation * Congestive heart failure requiring hospitalisation or medical intervention * Arrhythmias * Hypertension * Hypotension Results show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs.
| Participants | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Composite Cardiovascular Adverse Events (AEs) | 6 |
Safety Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the Clinical Endpoint Adjudication Committee (CEAC), were considered for this endpoint. Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit.
| week | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Time to First Composite Cardiovascular Safety AE | NA (NA to NA) |
Safety Results show the number of trial participants and their status of s-phosphate \<2 mg/dL, at any time from baseline to week 26.
| Participants | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Yes | 8 |
| No | 94 |
Efficacy. Change in Hb from baseline to week 2, 13, and 26.
| g/dL | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Week 2 | 1.23 ± 1.40 |
| Week 13 | 1.73 ± 1.83 |
| Week 26 | 1.34 ± 1.93 |
Efficacy. Change in s-ferritin from baseline to week 2, 13, and 26.
| ng/mL | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Week 2 | 255.6 ± 177.9 |
| Week 13 | 87.9 ± 123.6 |
| Week 26 | 93.9 ± 180.4 |
Efficacy Change in transferrin saturation (TSAT) from baseline to week 2, 13, and 26. TSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron.
| percentage of saturation | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Week 2 | 8.16 ± 11.87 |
| Week 13 | 4.42 ± 10.81 |
| Week 26 | 1.78 ± 10.63 |
Efficacy. Change in s-iron from baseline to week 2, 13, and 26.
| μg/dL | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Week 2 | 21.1 ± 50.5 |
| Week 13 | 10.7 ± 45.4 |
| Week 26 | 4.0 ± 44.1 |
Collected over From the time subjects signed the informed consent form (CRF) until they completed the trial, all adverse events (AEs) or serious adverse events (SAEs) were recorded in the CRF. The actual study duration was 6 months (or shorted if the trial was discontinued). Overall, eligible subjects participated in the trial for approximately 6.5 months (including a 14-day screening period).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Iron Isomaltoside/Ferric Derisomaltose | 1/193 (0.5%) | 13/102 (12.7%) | 17/102 (16.7%) |
| Event | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Chronic kidney diseaseRenal and urinary disorders | 2/102 |
| AppendicitisInfections and infestations | 1/102 |
| CellulitisInfections and infestations | 1/102 |
| EndometritisInfections and infestations | 1/102 |
| Cardiac failure congestiveCardiac disorders | 1/102 |
| Chest painGeneral disorders | 1/102 |
| FallInjury, poisoning and procedural complications | 1/102 |
| HypocalcaemiaMetabolism and nutrition disorders | 1/102 |
| Neck painMusculoskeletal and connective tissue disorders | 1/102 |
| MenorrhagiaReproductive system and breast disorders | 1/102 |
| Event | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| FatigueGeneral disorders | 3/102 |
| Abdominal painGastrointestinal disorders | 3/102 |
| Urinary tract infectionInfections and infestations | 3/102 |
| DizzinessNervous system disorders | 3/102 |
| HeadacheNervous system disorders | 3/102 |
| HypertensionVascular disorders | 3/102 |
| AnaemiaBlood and lymphatic system disorders | 3/102 |
| Age, Categorical(Participants) | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 82 |
| >=65 years | 21 |
| Age, Continuous(years) | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Mean | 49.9 ± 15.7 |
| Age, Customized(Participants) | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| 18-64 years | 82 |
| 65-84 years | 18 |
| >84 years | 3 |
| Sex: Female, Male(Participants) | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Female | 87 |
| Male | 16 |
| Ethnicity (NIH/OMB)(Participants) | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Hispanic or Latino | 46 |
| Not Hispanic or Latino | 57 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 41 |
| White | 60 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| United States | 103 |
| Current smoker(Participants) | Iron Isomaltoside/Ferric Derisomaltose |
|---|---|
| Yes | 8 |
| No | 95 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2017 to primary completion in Jun 2018, 17 months.
Results were first posted in Mar 2020, 1 year 8 months after primary completion. A results delay was requested in May 2019.
Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron isomaltoside 1000